ADVANCED BIOSENSING FOR MOLECULAR AND CELLULAR BIOMARKERS

适用于分子和细胞生物标志物的先进生物传感

基本信息

项目摘要

Present medical tests are largely performed in conditioned laboratories by highly trained personel with access to stable power and a constant supply of reagents. In many situations, however, it is valuable to have point-of-analysis or point-of-care capabilities. For example, environmental factors may best be evaluated onsite to avoid transportation of samples, to provide a real-time warning, when working in third world countries, or when working in challenging and hostile environments. The long term aim of this project is to develop a paradigm for a fully integrated platform for performing complex protein assays in the field. The system consists of a programmable microfluidic sample processing device called a cellular automaton coupled to a novel Hall-effect electrical sensor. This analysis system will be developed to detect PAH-protein adducts that mutagenic and carcenogenic challenges. However, the development of this general platform for immunodetection of targets will also find wide application in biomedical research, pathogen and infectious disease detection. Our overall goal will be addressed by the following specific aims: 1. A microfluidic automaton will be developed that is a programmable microfluidic device for performing fluidic and sample preparation operations at the nanoliter scale. This device will be developed and tested to perform the operations necessary to do basic optically detected ELISA analyzes of PAH-protein adducts. 2. In parallel, the Boser group will design and fabricate a set of advanced Hall Sensor chips that are optimized for mating with the automaton and detecting the immunoassay process. 3. The next step will demonstrate the integration of the automaton sample preparation with the Hall sensor for the detection of PAH-protein adducts. Once the assays are demonstrated to be compatible, the Hall sensor will be directly coupled with the automaton to form a prototype integrated analysis system. In the final aim a fully integrated electronic interface and low-cost disposable microfluidic cartridges and instrument will be developed to perform sample preprocessing, incubation, mixing with reagents, and detection of the analyte automatically in the cartridge. This project leverages microfluidic sample preparation and state-of-the-art detection with the PAH assay developed in Project 1 of this proposal. These technologies will lead to devices and methods for early detection and better information that will lead to more accurate diagnosis and targeted treatments.
目前的医学试验主要是在有条件的实验室中由训练有素的人员进行的,这些人员有稳定的电力和持续的试剂供应。然而,在许多情况下,具有分析点或护理点功能是有价值的。例如,环境因素最好在现场进行评估

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Bernhard E Boser其他文献

Bernhard E Boser的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Bernhard E Boser', 18)}}的其他基金

ADVANCED BIOSENSING FOR MOLECULAR AND CELLULAR BIOMARKERS
适用于分子和细胞生物标志物的先进生物传感
  • 批准号:
    7342288
  • 财政年份:
    2007
  • 资助金额:
    $ 42.57万
  • 项目类别:
ADVANCED BIOSENSING FOR MOLECULAR AND CELLULAR BIOMARKERS
适用于分子和细胞生物标志物的先进生物传感
  • 批准号:
    8102123
  • 财政年份:
  • 资助金额:
    $ 42.57万
  • 项目类别:
ADVANCED BIOSENSING FOR MOLECULAR AND CELLULAR BIOMARKERS
适用于分子和细胞生物标志物的先进生物传感
  • 批准号:
    7630608
  • 财政年份:
  • 资助金额:
    $ 42.57万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 42.57万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 42.57万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 42.57万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 42.57万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 42.57万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 42.57万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 42.57万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 42.57万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 42.57万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 42.57万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了